Results 81 to 90 of about 101,340 (329)

Characterisation of AmphiAmR11, an amphioxus (Branchiostoma floridae) D2-dopamine-like G protein-coupled receptor.

PLoS ONE, 2013
The evolution of the biogenic amine signalling system in vertebrates is unclear. However, insights can be obtained from studying the structures and signalling properties of biogenic amine receptors from the protochordate, amphioxus, which is an ...
Asha L Bayliss, Peter D Evans
doaj   +1 more source

Dysfunctional play and dopamine physiology in the Fischer 344 rat

, 2011
Juvenile Fischer 344 rats are known to be less playful than other inbred strains, although the neurobiological substrate(s) responsible for this phenotype is uncertain.
Akopian, Akopian, Akopian, Alcaro, Alessandri, Almeida, Baldwin, Bamford, Basar, Beatty, Beatty, Bell, Berridge, Breier, Broderick, Burgdorf, Burgdorf, Burghardt, Burghardt, Burghardt, Cadoni, Cadoni, Calabresi, Chambers, Cheng, Cordier, Crawford, Crawley, Cynthia A. Crawford, Davis, Depoortere, Fagen, Feifel, Field, Fleckenstein, Gainetdinov, Garnik Akopian, Garris, Geyer, Glowa, Gomez-Serrano, Gonon, Gordon, Guitart, Gulley, Guo, Gurden, Hariri, Harris, Helmeste, Huang, Huang, Hubbard, Humphries, Ikemoto, John P. Walsh, Kerr, Knutson, Kolomiets, Kosten, Leblois, Leipold, McGraw La, Meaney, Miles, Niesink, Panksepp, Panksepp, Panksepp, Panksepp, Panksepp, Patel, Patel, Pellegrini, Pellis, Pellis, Pellis, Pellis, Pellis, Pellis, Pellis, Pellis, Pellis, Petzinger, Pliszka, Reif, Robinson, Romeo, Sagvolden, Schulte, Sills, Siviy, Siviy, Siviy, Siviy, Siviy, Siviy, Skuse, Smith, Smith, Spear, Spinka, Stamford, Stephen M. Siviy, Stohr, Sulzer, Surmeier, Swerdlow, Swerdlow, Swerdlow, Tang, Terranova, Trezza, Trezza, Trezza, Trezza, Tripp, Van den Berg, Vanderschuren, Vanderschuren, Vanderschuren, Varty, Villar, Volkow, Voorn, Walker, Young   +126 more
core   +1 more source

Activities of bone morphogenetic proteins in prolactin regulation by somatostatin analogs in rat pituitary GH3 cells [PDF]

, 2011
Involvement of the pituitary BMP system in the modulation of prolactin (PRL) secretion regulated by somatostatin analogs, including octreotide (OCT) and pasireotide (SOM230), and a dopamine agonist, bromocriptine (BRC), was examined in GH3 cells.
Inagaki, Kenichi, Iwasaki, Yasumasa, Makino, Hirofumi, Miyoshi, Tomoko, Nakamura, Eri, Ogura, Toshio, Otsuka, Fumio, Suzuki, Jiro, Tsukamoto, Naoko   +8 more
core   +1 more source

Genetics of Response to ECT, TMS, Ketamine and Esketamine

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, EarlyView.
ABSTRACT Treatment‐resistant mood disorders are often managed with intensive interventions that include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), ketamine, and esketamine, but the role of genetics in clinical response to those interventions is yet to be clearly determined.
Clio E. Franklin, Murat Altinay, Kala Bailey, Mahendra T. Bhati, Brent R. Carr, Susan K. Conroy, Khurshid Khurshid, William M. McDonald, Brian J. Mickey, James W. Murrough, Sean M. Nestor, Thomas Nickl‐Jockschat, Irving M. Reti, Gerard Sanacora, Nicholas T. Trapp, Biju Viswanath, Jesse H. Wright, Peter P. Zandi, James B. Potash   +18 more
wiley   +1 more source

Adenosine A𝟐A Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease

Parkinson's Disease, 2012
Parkinson's disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra. Current treatments for PD focus on dopaminergic therapies, including L-dopa and dopamine receptor agonists.
Carina J. Bleickardt, Abigail L. LaShomb, Carrie E. Merkel, Robert A. Hodgson   +3 more
doaj   +1 more source

Acromegaly: Beyond surgery

Indian Journal of Endocrinology and Metabolism, 2013
Acromegaly is characterized by chronic, excess secretion of growth hormone (GH) from a pituitary adenoma, and elevated hepatic insulin-like growth factor 1 (IGF-1) levels.
Gaya Thanabalasingham, Ashley B Grossman
doaj   +1 more source

Dopamine Agonists: From the 1970s to Today [PDF]

Neuroendocrinology, 2019
The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting pituitary tumors, starting from the 1970s up to today, highlighting that normalization of PRL levels,
Auriemma R. S., Pirchio R., DE ALCUBIERRE, DARIO, Pivonello R., Colao A.   +4 more
openaire   +6 more sources

Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress [PDF]

, 2015
In human addicts, drug relapse and craving are often provoked by stress. Since 1995, this clinical scenario has been studied using a rat model of stress-induced reinstatement of drug seeking.
A Cippitelli, A Cippitelli, A Cippitelli, A Ettenberg, A Ettenberg, A Plaza-Zabala, A Sekino, A Van't Veer, AC Hansson, AD Le, AD Le, AD Le, AD Le, AD Le, AD Le, AD Le, AD Le, AD Le, AE Higley, AM Chirila, AM Polter, AM Thierry, AN Carey, Anh D Lê, AS Kreibich, AY Deutch, B Boutrel, B Lee, B Ribeiro Do Couto, B Setlow, B Wang, B Wang, B Wang, B Wang, B Wang, BB Land, BH Westerink, BL Lewis, BM Cox, BR Lee, C Cifani, C Li, CD Schmoutz, CJ Sanchez, CJ Sanchez, CK Nielsen, CL Pickens, CP Ford, CP O'Brien, CR Gerfen, D Economidou, D Epstein, D Funk, D Funk, D Highfield, D Highfield, D Highfield, D Liu, D Rodaros, D Rotllant, David A Baker, DC Glass, DEJ Redmond, DH Epstein, DJ Calu, DJ Calu, DM Buffalari, DM Buffalari, DM Buffalari, Douglas Funk, DR Gehlert, DR Staub, DS Zahm, DT George, DW Schulz, DW Self, E Krupitsky, EA Stone, EB Margolis, EJ Khantzian, EN Graf, EN Graf, EP Zorrilla, EP Zorrilla, F Chaouloff, F Cohen, F Georges, F Leri, F Sedki, F Weiss, FC Cruz, FJ White, G Aston-Jones, G de Guglielmo, G Zislis, GF Koob, GP Chrousos, GR Valdez, H Selye, H Yamada, HC Fox, HC Fox, J Jenkins, J Stewart, J Wang, JA Deutch, JA Gray, JA Simms, JC Umhau, JD Bremner, JD Bremner, JD Shepard, JE LeDoux, JE Morley, JJ Anker, JJ Anker, JK Richards, JK Seamans, JL McGaugh, JM Blacktop, JM Bossert, JM Bossert, JM Bossert, JM Fritschy, JN Cleck, John R Mantsch, JP McLaughlin, JP Schroeder, JR Glowa, JR Mantsch, JR Mantsch, JR Mantsch, JR Mantsch, JR McReynolds, JR Schank, JR Schank, JR Schank, JV Aldrich, JV Aldrich, K McFarland, K Van Pett, KJ Jackson, KL Conrad, KL Shelton, L Lu, L Lu, L Lu, L Lu, L Zhou, LA Briand, LE Kwako, LG Kirby, LK Vaughn, M Davis, M Davis, M Heilig, M Sakanaka, MA Ungless, MB Bannon, MD Cassell, ME Bouton, ME Bouton, ME Carroll, MEP Seligman, MF Dallman, MK Greenwald, ML Jobes, ML Price, MM Moran-Santa Maria, MM Moran-Santa Maria, MR Bruchas, MR Bruchas, MT Stefanik, MW Feltenstein, MW Feltenstein, MW Hale, N Capriles, N Omelchenko, N Sidhpura, NA Chen, NM Graziane, O Vranjkovic, O Vranjkovic, P Enrico, PE Sawchenko, PJ Fletcher, PM Beardsley, PM Beardsley, PS Regier, PV Piazza, PW Kalivas, PW Kalivas, PW Kalivas, PW Marinelli, R Ciccocioppo, R Haynes, R Kvetnansky, R Martin-Fardon, R Mongeau, R Sinha, R Sinha, R Sinha, R Sinha, R Sinha, R Sinha, R Sinha, R Sinha, R Takahata, RC Pierce, RC Twining, RD Weiss, RE See, RE See, RJ Smith, RM Gold, RP Vertes, RP Vertes, RP Waters, RY Moore, S Cabib, S Cohen, S Erb, S Erb, S Erb, S Erb, S Erb, S Erb, S Erb, S Fanous, S Geisler, S Grimwood, S Shiffman, S Stopponi, S Stopponi, S Stopponi, S Tobin, S Tobin, SA Flavin, SE Back, SF Maier, SF Maier, SG Nair, SG Nair, SG Nair, SH Ahmed, SH Ahmed, SL Grella, SM Antelman, SO Eans, SR Bornstein, SR Sesack, SV Mahler, SV Mahler, T Holdstock, T Maric, TL Bale, TR Kosten, U Shalev, U Shalev, U Shalev, U Shalev, U Shalev, U Shalev, UE Ghitza, V Deroche, VA Redila, WA Hunt, WB Cannon, WM Meil, X Liu, X Liu, X Wang, Y Buczek, Y Figueroa-Guzman, Y Nawata, Y Shaham, Y Shaham, Y Shaham, Y Shaham, Y Shaham, Y Shaham, Y Shaham, Y Silberman, Y Zhao, Yavin Shaham, YW Chen, YY Ma, YY Ma, Z Sarnyai, ZJ Brown, ZJ Brown, ZX Xi   +291 more
core   +2 more sources

Contribution of Addictovigilance data to assess adverse‐events linked to psychoactive substances in children and adolescents

British Journal of Clinical Pharmacology, EarlyView.
Aims We sought to characterize adverse events and deaths associated with the use of psychoactive substances in children and adolescents. Methods Two French Addictovigilance databases were analysed: spontaneous reports and deaths over the period 2016–2021, in subjects aged 10–<18 years. An unsupervised classification was implemented on consumption data (
Hélène Peyrière, Anne Batisse, Nathalie Fouilhé Sam‐Laï, Amélie Daveluy, Christine Fournier‐Choma, Sylvie Deheul, Cécile Chevalier, Clémence Lacroix, Valérie Gibaja, Aurélie Aquizerate, Stéphanie Pain, Emilie Jouanjus, Marie‐Christine Picot, Erika Nogue   +13 more
wiley   +1 more source

New information of dopaminergic agents based on quantum chemistry calculations

Scientific Reports, 2020
Dopamine is an important neurotransmitter that plays a key role in a wide range of both locomotive and cognitive functions in humans. Disturbances on the dopaminergic system cause, among others, psychosis, Parkinson’s disease and Huntington’s disease ...
Guillermo Goode-Romero, Ulrika Winnberg, Laura Domínguez, Ilich A. Ibarra, Rubicelia Vargas, Elisabeth Winnberg, Ana Martínez   +6 more
doaj   +1 more source